Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma von Daud, Adil I, Wolchok, Jedd D, Robert, Caroline, Hwu, Wen-Jen, Weber, Jeffrey S, Ribas, Antoni, Hodi, F Stephen, Joshua, Anthony M, Kefford, Richard, Hersey, Peter, Joseph, Richard, Gangadhar, Tara C, Dronca, Roxana, Patnaik, Amita, Zarour, Hassane, Roach, Charlotte, Toland, Grant, Lunceford, Jared K, Li, Xiaoyun Nicole, Emancipator, Kenneth, Dolled-Filhart, Marisa, Kang, S Peter, Ebbinghaus, Scot, Hamid, Omid

Volltext

Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma von Daud, Adil I, Loo, Kimberly, Pauli, Mariela L, Sanchez-Rodriguez, Robert, Sandoval, Priscila Munoz, Taravati, Keyon, Tsai, Katy, Nosrati, Adi, Nardo, Lorenzo, Alvarado, Michael D, Algazi, Alain P, Pampaloni, Miguel H, Lobach, Iryna V, Hwang, Jimmy, Pierce, Robert H, Gratz, Iris K, Krummel, Matthew F, Rosenblum, Michael D

Volltext

Intratumoral Delivery of Plasmid IL12 Via Electroporation Leads to Regression of Injected and Noninjected Tumors in Merkel Cell Carcinoma von Bhatia, Shailender, Longino, Natalie V., Miller, Natalie J., Kulikauskas, Rima, Iyer, Jayasri G., Ibrani, Dafina, Blom, Astrid, Byrd, David R., Parvathaneni, Upendra, Twitty, Christopher G., Campbell, Jean S., Le, Mai H., Gargosky, Sharron, Pierce, Robert H., Heller, Richard, Daud, Adil I., Nghiem, Paul

Volltext

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo von Posch, Christian, Moslehi, Homayoun, Feeney, Luzviminda, Green, Gary A., Ebaee, Anoosheh, Feichtenschlager, Valentin, Chong, Kim, Peng, Lily, Dimon, Michelle T., Phillips, Thomas, Daud, Adil I., McCalmont, Timothy H., LeBoit, Philip E., Ortiz-Urda, Susana

Volltext

Intratumoral therapies and in-situ vaccination for melanoma von Huppert, Laura A., Daud, Adil I.

Volltext

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma von DAUD, Adil I, DECONTI, Ronald C, HELLER, Richard, ANDREWS, Stephanie, URBAS, Patricia, RIKER, Adam I, SONDAK, Vernon K, MUNSTER, Pamela N, SULLIVAN, Daniel M, UGEN, Kenneth E, MESSINA, Jane L

Volltext

Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma von Rasco, Drew W., Medina, Theresa, Corrie, Pippa, Pavlick, Anna C., Middleton, Mark R., Lorigan, Paul, Hebert, Chris, Plummer, Ruth, Larkin, James, Agarwala, Sanjiv S., Daud, Adil I., Qiu, Jiaheng, Bozon, Viviana, Kneissl, Michelle, Barry, Elly, Olszanski, Anthony J.

Volltext

Phenotypic and Functional Analysis of Dendritic Cells and Clinical Outcome in Patients With High-Risk Melanoma Treated With Adjuvant Granulocyte Macrophage Colony-Stimulating Facto... von DAUD, Adil I, MIRZA, Noweeda, GABRILOVICH, Dmitry, LENOX, Brianna, ANDREWS, Stephanie, URBAS, Patricia, GAO, Gui X, LEE, Ji-Hyun, SONDAK, Vernon K, RIKER, Adam I, DECONTI, Ronald C

Volltext

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin von TOLCHER, Anthony W, MITA, Alain, KEATING, Anne, ANTONIA, Scott, LEWIS, Lionel D, GARRETT, Christopher R, TILL, Elizabeth, DAUD, Adil I, PATNAIK, Amita, PAPADOPOULOS, Kyri, TAKIMOTO, Chris, BARTELS, Pamela

Volltext

Metastatic melanoma to small bowel: metastasectomy is supported in the era of immunotherapy and checkpoint inhibitors von Wong, Paul, Wisneski, Andrew D, Tsai, Katy K, Chang, Tammy T, Hirose, Kenzo, Nakakura, Eric K, Daud, Adil I, Maker, Ajay V, Corvera, Carlos U

Volltext

In-field and abscopal response after short-course radiation therapy in patients with metastatic Merkel cell carcinoma progressing on PD-1 checkpoint blockade: a case series von Xu, Melody J, Wu, Susan, Daud, Adil I, Yu, Siegrid S, Yom, Sue S

Volltext

Valproic acid alters chromatin structure by regulation of chromatin modulation proteins von MARCHION, Douglas C, BICAKU, Elona, DAUD, Adil I, SULLIVAN, Daniel M, MUNSTER, Pamela N

Volltext

Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma von Haugh, Alexandra, Daud, Adil I.

Volltext

A natural killer–dendritic cell axis defines checkpoint therapy–responsive tumor microenvironments von Barry, Kevin C., Hsu, Joy, Broz, Miranda L., Cueto, Francisco J., Binnewies, Mikhail, Combes, Alexis J., Nelson, Amanda E., Loo, Kimberly, Kumar, Raj, Rosenblum, Michael D., Alvarado, Michael D., Wolf, Denise M., Bogunovic, Dusan, Bhardwaj, Nina, Daud, Adil I., Ha, Patrick K., Ryan, William R., Pollack, Joshua L., Samad, Bushra, Asthana, Saurabh, Chan, Vincent, Krummel, Matthew F.

Volltext

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial von DAUD, Adil I, DAWSON, Jana, MUNSTER, Pamela N, DECONTI, Ronald C, BICAKU, Elona, MARCHION, Douglas, BASTIEN, Sem, HAUSHEER, Frederick A, LUSH, Richard, NEUGER, Anthony, SULLIVAN, Daniel M

Volltext

Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity von Binnewies, Mikhail, Mujal, Adriana M., Pollack, Joshua L., Combes, Alexis J., Hardison, Emily A., Barry, Kevin C., Tsui, Jessica, Ruhland, Megan K., Kersten, Kelly, Abushawish, Marwan A., Spasic, Marko, Giurintano, Jonathan P., Chan, Vincent, Daud, Adil I., Ha, Patrick, Ye, Chun J., Roberts, Edward W., Krummel, Matthew F.

Volltext

Negative but not futile: MAGE-A3 immunotherapeutic for melanoma von Daud, Adil I

Volltext

Distinguishing between help and harm: Helper T cell subsets and immune-related adverse events von Haugh, Alexandra M, Daud, Adil I

Volltext

The Liver-Immunity Nexus and Cancer Immunotherapy von Lee, James C, Green, Michael D, Huppert, Laura A, Chow, Christine, Pierce, Robert H, Daud, Adil I

Volltext

Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade von Tsai, Katy K., Pampaloni, Miguel H., Hope, Charity, Algazi, Alain P., Ljung, Britt-Marie, Pincus, Laura, Daud, Adil I.

Volltext